CompletedNCT01050582
Growth and puberty during antipsychotic treatment in children
About this title
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Read the official source — NCT01050582Medication studyAges 8–16Multiple countriesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 8 years to 16 years.
- Listed locations
- San Francisco and 27 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 244
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Belgium, Germany, ...
- Age range
- From 8 Years to 16 Years
- Official registry ID
- NCT01050582
- Official title
Show the full official title
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Get this study by email
Recruitment & locations
CompletedSan Francisco, United States · Aurora, United States · Altamonte Springs, United States
25 more locations
- Gainesville, United States
- Smyrna, United States
- Naperville, United States
- Indianapolis, United States
- Valparaiso, United States
- Boston, United States
- Cambridge, United States
- Glen Oaks, United States
- Cleveland, United States
- Columbus, United States
- Antwerp, Belgium
- Freiburg im Breisgau, Germany
- Jena, Germany
- Mannheim, Germany
- München, Germany
- Tübingen, Germany
- Ulm, Germany
- Würzburg, Germany
- Athens, Greece
- Nijmegen, Netherlands
- Gdansk, Poland
- Kielce, Poland
- Lódź, Poland
- Sosnowiec, Poland
- Warsaw, Poland
Questions about this study
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Risperidone and Other atypical antipsychotic drugs.
Who was this study for?
Listed age limits: 8 years to 16 years.
Want to explore more studies?
Explore studiesRelated studies
A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ...
Paliperidone and valproic acid levels in psychosis and bipolarity